CG Oncology (CGON) director sells 1,000 at $43.25 after exercise

CG Oncology (CGON): Form 4 insider activity — A director reported transactions on 10/13/2025.

Rhea-AI Filing Summary

CG Oncology (CGON): Form 4 insider activity — A director reported transactions on 10/13/2025. The reporting person exercised 1,000 stock options at $0.60 (Code M) and sold 1,000 shares at $43.25 (Code S).

The sale was effected under a Rule 10b5-1 trading plan adopted on September 6, 2024. Following these transactions, the reporting person held 0 shares of common stock directly and 118,077 derivative securities (director stock options) directly.

Insider Trade Summary

Exercise and Sale: 1,000 shares ($43K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider POST LEONARD E

Role Director

Sold 1,000 shs ($43K)

Approx. gross sale proceeds $43K

Approx. exercise cost $600.00

Approx. pre-tax spread $43K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy)	1,000	$0.00	$0.00
Exercise	Common Stock	1,000	$0.60	$600.00
Sale	Common Stock	1,000	$43.25	$43K

Holdings After Transaction: Director Stock Option (right to buy) — 118,077 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.
2. F2. Fully vested

FAQ

What insider transaction did CGON report on this Form 4?

A director exercised 1,000 options at $0.60 and sold 1,000 shares at $43.25 on 10/13/2025.

Was the CGON share sale under a 10b5-1 plan?

Yes. The sale was effected under a Rule 10b5-1 trading plan adopted on September 6, 2024.

How many CGON shares does the insider hold after the transactions?

The reporting person held 0 shares of common stock directly after the reported sale.

How many CGON options does the insider hold after the transactions?

The reporting person held 118,077 derivative securities (director stock options) directly after the transactions.

What were the transaction codes on the CGON Form 4?

Code M for the option exercise and Code S for the sale.

What was the exercise price and size of the CGON option exercise?

The director exercised 1,000 options at an exercise price of $0.60.

What is the insider’s relationship to CGON?

The reporting person is a Director of CG Oncology, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/15/2025 - 12:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

POST LEONARD E

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

400 SPECTRUM CENTER DRIVE, SUITE 2040

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/13/2025		M		1,000	A	$0.6	1,000	D
Common Stock	10/13/2025		S(1)		1,000	D	$43.25	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$0.6	10/13/2025		M			1,000	(2)	07/08/2028	Common Stock	1,000	$0	118,077	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.

2. Fully vested

	/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.